Publicaciones en colaboración con investigadores/as de Hackensack University Medical Center (6)

2021

  1. Idecabtagene vicleucel in relapsed and refractory multiple myeloma

    New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716

  2. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

    Blood Cancer Journal, Vol. 11, Núm. 6

2020

  1. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

    Leukemia, Vol. 34, Núm. 12, pp. 3298-3309

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2013

  1. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma

    Journal of Clinical Oncology

2009

  1. Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma

    CLINICAL LYMPHOMA & MYELOMA